These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 1977185)

  • 41. Aminosalicylates in the treatment of inflammatory bowel disease.
    Sutherland LR
    Inflamm Bowel Dis; 1998 May; 4(2):113. PubMed ID: 9687217
    [No Abstract]   [Full Text] [Related]  

  • 42. [Recent therapeutic modalities in chronic inflammatory bowel diseases: 4- or 5-aminosalicylic acid?].
    Allgayer H; Klotz U; Böhne P; Schmidt M; Kruis W
    Z Gastroenterol; 1994 Nov; 32(11):647-50. PubMed ID: 7886975
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Treatment of chronic inflammatory intestinal diseases with 5-aminosalicylic acid].
    Malchow H
    Internist (Berl); 1987 Jan; 28(1):14-20. PubMed ID: 2883152
    [No Abstract]   [Full Text] [Related]  

  • 44. Salicylates for inflammatory bowel disease.
    Travis SP; Jewell DP
    Baillieres Clin Gastroenterol; 1994 Jun; 8(2):203-31. PubMed ID: 7949456
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Desensitization to sulfasalazine.
    Hessemer CA; Schinagl EF
    Am J Gastroenterol; 1993 Mar; 88(3):460-1, 462. PubMed ID: 8094941
    [No Abstract]   [Full Text] [Related]  

  • 46. [Combination of purine analogues and aminosalicylates in patients with inflammatory bowel disease: why and how?].
    Jomni T; Dray X; Marteau P
    Gastroenterol Clin Biol; 2007; 31(8-9 Pt 1):758-60. PubMed ID: 17925782
    [No Abstract]   [Full Text] [Related]  

  • 47. [Aminosalicylates in the treatment of chronic inflammatory bowel diseases].
    Hartmann F; Plauth M
    Internist (Berl); 1990 Nov; 31(11):702-6. PubMed ID: 2289856
    [No Abstract]   [Full Text] [Related]  

  • 48. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer?
    Bernstein CN; Blanchard JF; Metge C; Yogendran M
    Am J Gastroenterol; 2003 Dec; 98(12):2784-8. PubMed ID: 14687833
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Prevention of recurrence of chronic inflammatory bowel diseases].
    Dölle W; Hartmann F
    Verh Dtsch Ges Inn Med; 1989; 95():322-6. PubMed ID: 2574922
    [No Abstract]   [Full Text] [Related]  

  • 50. [Pregnancy outcome in inflammatory bowel diseases].
    Tennenbaum R; Marteau P; Elefant E; Rambaud JC; Modigliani R; Gendre JP; Cosnes J
    Gastroenterol Clin Biol; 1999 May; 23(5):464-9. PubMed ID: 10429848
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group.
    Rutgeerts P
    Aliment Pharmacol Ther; 1989 Apr; 3(2):183-91. PubMed ID: 2577483
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunopharmacology of 5-aminosalicylic acid and of glucocorticoids in the therapy of inflammatory bowel disease.
    Nikolaus S; Fölscn U; Schreiber S
    Hepatogastroenterology; 2000; 47(31):71-82. PubMed ID: 10690587
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Review: new aminosalicylic acid derivatives for the treatment of inflammatory bowel disease.
    Arvind AS; Farthing MJ
    Aliment Pharmacol Ther; 1988 Aug; 2(4):281-9. PubMed ID: 2979251
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Medical management of specific clinical presentations.
    Bitton A; Peppercorn MA
    Gastroenterol Clin North Am; 1995 Sep; 24(3):541-58. PubMed ID: 8809235
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
    Nakajima H; Munakata A; Yoshida Y
    J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sulfasalazine. Multiplicity of action.
    Gaginella TS; Walsh RE
    Dig Dis Sci; 1992 Jun; 37(6):801-12. PubMed ID: 1350243
    [No Abstract]   [Full Text] [Related]  

  • 57. Treatment of inflammatory bowel disease: safety and tolerability issues.
    Navarro F; Hanauer SB
    Am J Gastroenterol; 2003 Dec; 98(12 Suppl):S18-23. PubMed ID: 14697914
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Active therapeutic moiety of sulphasalazine.
    van Hees PA; van Tongeren JH; Bakker JH; van Lier HJ
    Lancet; 1978 Feb; 1(8058):277. PubMed ID: 74700
    [No Abstract]   [Full Text] [Related]  

  • 59. New light on the anti-colitic actions of therapeutic aminosalicylates: the role of heme oxygenase.
    Whittle BJ; Varga C
    Pharmacol Rep; 2010; 62(3):548-56. PubMed ID: 20631420
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New approaches may aid patients with inflammatory bowel disease.
    Cotton P
    JAMA; 1990 Jun; 263(23):3121-2. PubMed ID: 2348514
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.